We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 560

Heenan Blaikie “grinds out” another win for Teva

  • Heenan Blaikie LLP
  • -
  • Canada
  • -
  • January 13 2014

On January 13, 2014, the Federal Court dismissed an application by Bristol-Myers Squibb, Gilead Sciences, LLC and Merck Sharp & Dohme Corp

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • October 16 2014

Canada Introduction 'Personalized medicine', in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs

Canada patented medicines: Federal Court of Appeal confirms mootness of innovator appeals after generic marketing authorization is granted

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • February 17 2015

"Asking a court to prohibit a notice of compliance after it has issued is like asking someone to close the barn door after the horses have escaped."

Bayer Inc. v. Cobalt Pharmaceuticals Company, 2013 FC 1061 : methods of medical treatment held unpatentable, promise of a patent must be explicit

  • Heenan Blaikie LLP
  • -
  • Canada
  • -
  • November 11 2013

On October 22, 2013, the Federal Court released its decision regarding Bayer's application to prohibit the Minister of Health from issuing Cobalt a

Expert opinion as to what “one would expect” is speculation, not evidence

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Listing patents against combination drugs in Canada ? Changes coming

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

Important recent trends in pharmaceutical patent litigation

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

From a patentee’s perspective, the patent litigation landscape in 2010 and continuing into 2011 appears to have shifted to a more hospitable environment for innovators

Federal court prohibits the approval of a generic prodrug CELLCEPT (mycophenolate mofetil)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 26 2011

On July 13, 2011, the Federal Court allowed an application by Hoffman La-Roche Limited (“Roche”), pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex Inc. (“Apotex”) in respect of its generic version of the drug mycophenolate mofetil (“MMF”) until after the expiry of Canadian Patent No. 1,333,285 (the “285 Patent”